Haizhong Feng

Dr. Haizhong Feng

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
JTJianming Tang
Jianming Tang
LYLi yanxin
Li yanxin
YSYouzhou Sang
Youzhou Sang
BYBo Yu
Bo Yu
DLDeguan Lv
Deguan Lv
HFHaizhong Feng
Haizhong Feng

14 November 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DLDeguan Lv
Deguan Lv
FJFeng Jia
Feng Jia
YHYanli Hou
Yanli Hou
YSYouzhou Sang
Youzhou Sang
AAAngel A. Alvarez
Angel A. Alvarez
HFHaizhong Feng
Haizhong Feng
Lysine acetyltransferase KAT6A is a chromatin regulator that contributes to histone modification and cancer, but the basis of its actions are not well understood. Here, we identify a KAT6A signaling pathway that facilitates glioblastoma (GBM), where it is upregulated. KAT6A expression was associated with GBM patient survival. KAT6A silencing suppressed cell proliferation, cell migration, colony formation, and tumor development in an orthotopic mouse xenograft model system. Mechanistic investigations demonstrated that KAT6A acetylates lysine 23 of histone H3 (H3K23), which recruits the nuclear receptor binding protein TRIM24 to activate PIK3CA transcription, thereby enhancing PI3K/AKT signaling and tumorigenesis. Overexpressing activated AKT or PIK3CA rescued the growth inhibition due to KAT6A silencing. Conversely, the pan-PI3K inhibitor LY294002 abrogated the growth-promoting effect of KAT6A. Overexpression of KAT6A or TRIM24, but not KAT6A acetyltransferase activity–deficient mutants or TRIM24 mutants lacking H3K23ac-binding sites, promoted PIK3CA expression, AKT phosphorylation, and cell proliferation. Taken together, our results define an essential role of KAT6A in glioma formation, rationalizing its candidacy as a therapeutic target for GBM treatment. Cancer Res; 77(22); 6190–201. ©2017 AACR.

13 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
DLDeguan Lv
Deguan Lv
YLYanxin Li
Yanxin Li
WZWeiwei Zhang
Weiwei Zhang
AAAngel A. Alvarez
Angel A. Alvarez
LSLina Song
Lina Song
HFHaizhong Feng
Haizhong Feng
Aberrant amplification and mutations of epidermal growth factor receptor (EGFR) are the most common oncogenic events in glioblastoma (GBM), but the mechanisms by which they promote aggressive pathogenesis are not well understood. Here, we determine that non-canonical histone signature acetylated H3 lysine 23 (H3K23ac)-binding protein tripartite motif-containing 24 (TRIM24) is upregulated in clinical GBM specimens and required for EGFR-driven tumorigenesis. In multiple glioma cell lines and patient-derived glioma stem cells (GSCs), EGFR signaling promotes H3K23 acetylation and association with TRIM24. Consequently, TRIM24 functions as a transcriptional co-activator and recruits STAT3, leading to stabilized STAT3-chromatin interactions and subsequent activation of STAT3 downstream signaling, thereby enhancing EGFR-driven tumorigenesis. Our findings uncover a pathway in which TRIM24 functions as a signal relay for oncogenic EGFR signaling and suggest TRIM24 as a potential therapeutic target for GBM that are associated with EGFR activation.

3 January 2023 in Hepatology
Verified
Journal Article
Open access
YCYibin Che
Yibin Che
GCGuoyu Chen
Guoyu Chen
QGQianqian Guo
Qianqian Guo
YDYourong Duan
Yourong Duan
HFHaizhong Feng
Haizhong Feng
QXQiang Xia
Qiang Xia
Export Background and Aims: Gut microbiota are recognized to be important for anticancer therapy, yet the underlying mechanism is not clear. Here, through the analysis of clinical samples, we identify the mechanism by which the gut microbial metabolite butyrate inhibits hepatocellular carcinoma (HCC) and then explore new strategies for HCC treatment. Approach and Results: In our study, we demonstrate that gut microbial metabolite butyrate improves anticancer therapy efficacy by regulating intracellular calcium homeostasis. Using liquid chromatography-mass spectrometry analysis, we found that butyrate metabolism is activated in HCC patients compared with healthy individuals. Butyrate levels are lower in the plasma of HCC patients by gas chromatography mass spectrometry (GC-MS) analysis. Butyrate supplementation or depletion of short-chain Acyl-CoA dehydrogenase (ACADS), a key enzyme for butyrate metabolism, significantly inhibits HCC proliferation and metastasis. Profiling analysis of genes upregulated by butyrate supplementation or ACADS knockdown reveals that calcium signaling pathway is activated, leading to dysregulation of intracellular calcium homeostasis and production of reactive oxygen species (ROS). Butyrate supplementation improves the therapy efficacy of a tyrosine kinase inhibitor sorafenib. Based on these findings, we developed butyrate and sorafenib co-encapsulated mPEG-PLGA-PLL (PEAL) nanoparticles (NPs) coated with anti-GPC3 antibody ([email protected]) to prolong the retention time of drugs and enhance drug targeting, leading to high anticancer efficacy. [email protected] NPs significantly reduce HCC progression. In addition, [email protected] NPs display excellent HCC targeting with excellent safety. Conclusions: In conclusion, our findings provide new insight into the mechanism by which the gut microbial metabolites inhibit HCC progression, suggesting a translatable therapeutics approach to enhance the clinical targeted therapeutic efficacy.

11 January 2006 in Plant Physiology
Verified
Journal Article
Open access
PDF file
XYXiang-Chun Yu
Xiang-Chun Yu
MLMei-Jun Li
Mei-Jun Li
GGGui-Feng Gao
Gui-Feng Gao
HFHaizhong Feng
Haizhong Feng
XGXue-Qing Geng
Xue-Qing Geng
DZDa-Peng Zhang
Da-Peng Zhang
It has been demonstrated that calcium plays a central role in mediating abscisic acid (ABA) signaling, but many of the Ca2+-binding sensory proteins as the components of the ABA-signaling pathway remain to be elucidated. Here we identified, characterized, and purified a 58-kD ABA-stimulated calcium-dependent protein kinase from the mesocarp of grape berries (Vitis vinifera × Vitis labrusca), designated ACPK1 (for ABA-stimulated calcium-dependent protein kinase1). ABA stimulates ACPK1 in a dose-dependent manner, and the ACPK1 expression and enzyme activities alter accordantly with the endogenous ABA concentrations during fruit development. The ABA-induced ACPK1 stimulation appears to be transient with a rapid effect in 15 min but also with a slow and steady state of induction after 60 min. ABA acts on ACPK1 indirectly and dependently on in vivo state of the tissues. Two inactive ABA isomers, (−)-2-cis, 4-trans-ABA and 2-trans, 4-trans-(±)-ABA, are ineffective for inducing ACPK1 stimulation, revealing that the ABA-induced effect is stereo specific to physiological active (+)-2-cis, 4-trans-ABA. The other phytohormones such as auxin indoleacetic acid, gibberellic acid, synthetic cytokinin N-benzyl-6-aminopurine, and brassinolide are also ineffective in this ACPK1 stimulation. Based on sequencing of the two-dimensional electrophoresis-purified ACPK1, we cloned the ACPK1 gene. The ACPK1 is expressed specifically in grape berry covering a fleshy portion and seeds, and in a developmental stage-dependent manner. We further showed that ACPK1 is localized in both plasma membranes and chloroplasts/plastids and positively regulates plasma membrane H+-ATPase in vitro, suggesting that ACPK1 may be involved in the ABA-signaling pathway.

13 August 2021 in Advanced Science
Verified
Journal Article
Open access
PDF file
BYBo Yu
Bo Yu
FLFei Luo
Fei Luo
BSBowen Sun
Bowen Sun
WLWenxue Liu
Wenxue Liu
QSQiqi Shi
Qiqi Shi
HFHaizhong Feng
Haizhong Feng
Aberrant SMAD3 activation has been implicated as a driving event in cancer metastasis, yet the underlying mechanisms are still elusive. Here, SMAD3 is identified as a nonhistone substrate of lysine acetyltransferase 6A (KAT6A). The acetylation of SMAD3 at K20 and K117 by KAT6A promotes SMAD3 association with oncogenic chromatin modifier tripartite motif‐containing 24 (TRIM24) and disrupts SMAD3 interaction with tumor suppressor TRIM33. This event in turn promotes KAT6A‐acetylated H3K23‐mediated recruitment of TRIM24–SMAD3 complex to chromatin and thereby increases SMAD3 activation and immune response‐related cytokine expression, leading to enhanced breast cancer stem‐like cell stemness, myeloid‐derived suppressor cell (MDSC) recruitment, and triple‐negative breast cancer (TNBC) metastasis. Inhibiting KAT6A in combination with anti‐PD‐L1 therapy in treating TNBC xenograft‐bearing animals markedly attenuates metastasis and provides a significant survival benefit. Thus, the work presents a KAT6A acetylation‐dependent regulatory mechanism governing SMAD3 oncogenic function and provides insight into how targeting an epigenetic factor with immunotherapies enhances the antimetastasis efficacy.